In CLL, PAK1 inhibitor IPA-3 inhibited cell proliferation, and its combination with ibrutinib resulted in a synergistic effect in ibrutinib-sensitive and -resistant cells, revealing its role in drug resistance [65]. The gene discussed is PAK1; the disease is B-cell chronic lymphocytic leukemia.